SG11201708441RA - Polypeptides targeting hiv fusion - Google Patents
Polypeptides targeting hiv fusionInfo
- Publication number
- SG11201708441RA SG11201708441RA SG11201708441RA SG11201708441RA SG11201708441RA SG 11201708441R A SG11201708441R A SG 11201708441RA SG 11201708441R A SG11201708441R A SG 11201708441RA SG 11201708441R A SG11201708441R A SG 11201708441RA SG 11201708441R A SG11201708441R A SG 11201708441RA
- Authority
- SG
- Singapore
- Prior art keywords
- hiv fusion
- targeting hiv
- polypeptides targeting
- polypeptides
- fusion
- Prior art date
Links
- 230000004927 fusion Effects 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- AIDS & HIV (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Immunology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562152271P | 2015-04-24 | 2015-04-24 | |
| US201562257474P | 2015-11-19 | 2015-11-19 | |
| PCT/US2016/027424 WO2016171980A1 (en) | 2015-04-24 | 2016-04-14 | Polypeptides targeting hiv fusion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201708441RA true SG11201708441RA (en) | 2017-11-29 |
Family
ID=55809237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201708441RA SG11201708441RA (en) | 2015-04-24 | 2016-04-14 | Polypeptides targeting hiv fusion |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US10407490B2 (es) |
| EP (2) | EP3985020A1 (es) |
| JP (3) | JP6894846B2 (es) |
| KR (1) | KR20170138558A (es) |
| CN (1) | CN107922474A (es) |
| AU (2) | AU2016252008B2 (es) |
| BR (1) | BR112017022790A2 (es) |
| CA (1) | CA2983276A1 (es) |
| CL (1) | CL2017002687A1 (es) |
| CO (1) | CO2017011583A2 (es) |
| CR (1) | CR20170482A (es) |
| DO (1) | DOP2017000246A (es) |
| EA (1) | EA035332B1 (es) |
| ES (1) | ES2884267T3 (es) |
| HK (1) | HK1243432A1 (es) |
| IL (1) | IL255122A0 (es) |
| MA (2) | MA41943A (es) |
| MX (1) | MX2017013687A (es) |
| PE (1) | PE20180162A1 (es) |
| PH (1) | PH12017501914A1 (es) |
| PT (1) | PT3286212T (es) |
| SG (1) | SG11201708441RA (es) |
| TW (1) | TW201643185A (es) |
| UY (1) | UY36650A (es) |
| WO (1) | WO2016171980A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106755100A (zh) * | 2017-02-20 | 2017-05-31 | 李因传 | 可控性hiv‑1基因组靶向编辑系统和其靶向载运系统 |
| WO2019123262A1 (en) | 2017-12-18 | 2019-06-27 | VIIV Healthcare UK (No.5) Limited | Antigen binding polypeptides |
| CN114605505B (zh) * | 2018-08-09 | 2023-01-31 | 东莞市朋志生物科技有限公司 | 用于检测hiv-1的合成肽 |
| WO2021081515A2 (en) * | 2019-10-25 | 2021-04-29 | Cidara Therapeutics, Inc. | Compositions and methods for the treatment of human immunodeficiency virus |
| CA3230492A1 (en) * | 2021-08-30 | 2023-03-09 | Kanglin Biotechnology (Hangzhou) Co., Ltd. | Gene sequence construct for gene therapy for hiv infection |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US5672502A (en) | 1985-06-28 | 1997-09-30 | Celltech Therapeutics Limited | Animal cell culture |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| US6048728A (en) | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| JP3051145B2 (ja) | 1990-08-28 | 2000-06-12 | 住友製薬株式会社 | 新規なポリエチレングリコール誘導体修飾ペプチド |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| JP3095175B2 (ja) | 1992-11-13 | 2000-10-03 | アイデック ファーマシューティカルズ コーポレイション | Ｂ細胞リンパ腫の治療のためのヒトｂリンパ球限定分化抗原に対するキメラ抗体と放射能標識抗体の療法利用 |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| PT971946E (pt) | 1997-01-21 | 2006-11-30 | Gen Hospital Corp | Selecção de proteínas utilizando fusões arn-proteína |
| US6261804B1 (en) | 1997-01-21 | 2001-07-17 | The General Hospital Corporation | Selection of proteins using RNA-protein fusions |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| AU2265701A (en) * | 1999-12-16 | 2001-06-25 | Tanox, Inc. | Anti-hiv-1 conjugates for treatment of hiv disease |
| US20050287153A1 (en) | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
| ES2564161T3 (es) | 2000-07-11 | 2016-03-18 | Research Corporation Technologies, Inc | Polipéptidos de anticuerpos artificiales |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| MXPA05002851A (es) * | 2002-09-27 | 2005-09-08 | Tanox Inc | Composiciones sinergicas para la prevencion y el tratamiento del sindrome de inmunodeficiencia adquirida. |
| PT2316852E (pt) | 2002-11-08 | 2014-06-23 | Ablynx Nv | Anticorpos de domínio único estáveis |
| SI1729795T1 (sl) | 2004-02-09 | 2016-04-29 | Human Genome Sciences, Inc. | Albuminski fuzijski proteini |
| US20070269422A1 (en) | 2006-05-17 | 2007-11-22 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| AR067584A1 (es) * | 2007-07-20 | 2009-10-14 | Hoffmann La Roche | Un conjugado de un anticuerpo contra la cd4 y peptidos antifusogenicos |
| EP2234646A2 (en) | 2007-12-27 | 2010-10-06 | Novartis AG | Improved fibronectin-based binding molecules and their use |
| PL2439212T3 (pl) | 2008-05-02 | 2017-06-30 | Novartis Ag | Ulepszone cząsteczki wiążące na bazie fibronektyny oraz ich zastosowanie |
| PL2356269T3 (pl) | 2008-10-31 | 2016-12-30 | Kompozycje białek rusztowania oparte na domenie fibronektyny typu III, sposoby i zastosowania | |
| GB0920944D0 (en) * | 2009-11-30 | 2010-01-13 | Biotest Ag | Agents for treating disease |
| US20130108653A1 (en) * | 2009-12-22 | 2013-05-02 | Shervin Bahrami | Bivalent molecules for hiv entry inhibition |
| PE20130238A1 (es) | 2010-04-13 | 2013-03-11 | Bristol Myers Squibb Co | Proteinas de dominio de armazon basadas en fibronectina que se unen a la proproteina convertasa subtilisina kexina tipo 9 (pcsk9) |
| TW201138808A (en) * | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
| RU2012148816A (ru) * | 2010-05-07 | 2014-06-20 | Ф. Хоффманн-Ля Рош Аг | Метод диагностики для определения клеток ex vivo |
| US9260496B2 (en) | 2010-12-22 | 2016-02-16 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind IL-23 |
| WO2012159164A1 (en) | 2011-05-23 | 2012-11-29 | Phylogica Limited | Method of determining, identifying or isolating cell-penetrating peptides |
| EA035150B1 (ru) | 2011-09-27 | 2020-05-06 | Янссен Байотек, Инк. | Способ получения белковых каркасов на основе фибронектинового домена типа iii с альтернативными поверхностями связывания |
| WO2014120891A2 (en) * | 2013-02-01 | 2014-08-07 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins |
| US20160152686A1 (en) * | 2013-03-13 | 2016-06-02 | Bristol-Myers Squibb Company | Fibronectin based scaffold domains linked to serum albumin or moiety binding thereto |
| CN103333255A (zh) * | 2013-06-28 | 2013-10-02 | 复旦大学 | 一种长效hiv‐1膜融合抑制剂 |
-
2016
- 2016-04-14 MX MX2017013687A patent/MX2017013687A/es unknown
- 2016-04-14 MA MA041943A patent/MA41943A/fr unknown
- 2016-04-14 CR CR20170482A patent/CR20170482A/es unknown
- 2016-04-14 CN CN201680036930.XA patent/CN107922474A/zh active Pending
- 2016-04-14 MA MA056222A patent/MA56222A/fr unknown
- 2016-04-14 BR BR112017022790-8A patent/BR112017022790A2/pt not_active IP Right Cessation
- 2016-04-14 EP EP21176464.2A patent/EP3985020A1/en active Pending
- 2016-04-14 EA EA201792269A patent/EA035332B1/ru not_active IP Right Cessation
- 2016-04-14 PT PT167188176T patent/PT3286212T/pt unknown
- 2016-04-14 US US15/568,830 patent/US10407490B2/en active Active
- 2016-04-14 ES ES16718817T patent/ES2884267T3/es active Active
- 2016-04-14 EP EP16718817.6A patent/EP3286212B1/en active Active
- 2016-04-14 CA CA2983276A patent/CA2983276A1/en not_active Abandoned
- 2016-04-14 JP JP2017555557A patent/JP6894846B2/ja active Active
- 2016-04-14 PE PE2017002311A patent/PE20180162A1/es unknown
- 2016-04-14 WO PCT/US2016/027424 patent/WO2016171980A1/en active Application Filing
- 2016-04-14 AU AU2016252008A patent/AU2016252008B2/en not_active Ceased
- 2016-04-14 SG SG11201708441RA patent/SG11201708441RA/en unknown
- 2016-04-14 KR KR1020177033985A patent/KR20170138558A/ko unknown
- 2016-04-22 UY UY0001036650A patent/UY36650A/es not_active Application Discontinuation
- 2016-04-22 TW TW105112708A patent/TW201643185A/zh unknown
-
2017
- 2017-10-18 IL IL255122A patent/IL255122A0/en unknown
- 2017-10-19 PH PH12017501914A patent/PH12017501914A1/en unknown
- 2017-10-23 CL CL2017002687A patent/CL2017002687A1/es unknown
- 2017-10-23 DO DO2017000246A patent/DOP2017000246A/es unknown
- 2017-11-14 CO CONC2017/0011583A patent/CO2017011583A2/es unknown
-
2018
- 2018-02-28 HK HK18102882.7A patent/HK1243432A1/zh unknown
-
2019
- 2019-08-07 US US16/533,941 patent/US11155602B2/en active Active
- 2019-09-06 AU AU2019226255A patent/AU2019226255A1/en not_active Abandoned
-
2020
- 2020-10-16 JP JP2020174288A patent/JP2021035951A/ja active Pending
-
2023
- 2023-02-03 JP JP2023014947A patent/JP7465378B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1249526A1 (zh) | 抗癌融合多肽 | |
| HK1244019A1 (zh) | 融合蛋白 | |
| ZA201706061B (en) | Anti-cancer fusion polypeptide | |
| GB201509413D0 (en) | Fusion protein | |
| HK1246316A1 (zh) | 細胞因子融合蛋白 | |
| HK1232136A1 (zh) | 融合蛋白 | |
| HK1232234A1 (zh) | 融合蛋白 | |
| HK1243432A1 (zh) | 靶向hiv融合物之多肽 | |
| GB201504691D0 (en) | Fusion protein | |
| SG10201911499TA (en) | Novel anti-angiogenic fusion polypeptides | |
| EP3353791A4 (en) | MAGNETIC COMPRESSION SUPPORTED FUSION | |
| HK1257937A1 (zh) | 融合蛋白 | |
| HK1253854A1 (zh) | 抗微生物融合肽 | |
| SG11201606501PA (en) | Nanobody-fluorescent protein fusion | |
| GB201602850D0 (en) | Fusion proteins | |
| GB201617799D0 (en) | Fusion polypeptide | |
| PT3298030T (pt) | Polipeptídeo de fusão anticancro | |
| GB201503789D0 (en) | Fusion polypeptide | |
| AP00903S1 (en) | M-kopa iv torch | |
| GB201517085D0 (en) | Torch | |
| GB201513489D0 (en) | Torch |